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OR (95% CI)IL-1 b 1.59 (0.30–8.45) 0.92 (0.32–2.60) 0.58 (0.10–3.32)
IL-6 0.27 (0.09–0.79)* 1.15 (0.52–2.52) 4.26 (1.32–13.82)*
IL-1 RA 0.69 (0.22–2.14) 0.55 (0.29–1.07) 0.81 (0.26–2.48)
sIL-6R 0.50 (0.12–2.13) 1.78 (0.54–5.90) 3.53 (0.83–15.13)
TNF-RII 0.29 (0.04–2.42) 0.28 (0.08–0.99)* 0.95 (0.12–7.59)
MCP-1 8.70 (1.46–51.66)* 0.40 (0.11–1.40) 0.05 (0.01–0.36)**
MIG 1.33 (0.73–2.44) 1.02 (0.63–1.65) 0.77 (0.42–1.39)
sBAFF 0.40 (0.13–1.30) 1.86 (0.88–3.93) 4.61 (1.39–15.31)**† values were log normal transformed prior to analysis
**or *p\ .01 or p\ .05, respectively, multinomial logistic regression.
Higher IL-6 levels significantly differentiated participants in
Group 2 from those in Groups 1 and 3. Group 3 had higher TNF-
RII compared to Group 1. Those with higher sBAFF levels were sig-
nificantly more likely to be in Group 2, while those with higher
MCP-1 levels were significantly more likely to be in Group 3.
Conclusion: Allogeneic HSCT survivors with differing cGVHD
symptom profiles were distinguished by significantly different levels
of IL-6, TNF-RII, MCP-1 and sBAFF. These data validate this new
symptom grouping system based on the Lee Chronic GVHD Symp-
tom Scale as a measure of cGVHD disease burden. IL-6, TNF-RII,
MCP-1 and sBAFF appear to be important biomarkers that reflect
specific cGVHD manifestations and merit further study.331
DONOR DENDRITIC CELLS INITIATE COUNTER-REGULATORY IMMUNE
RESPONSES AND GVL EFFECTS IN ALLLOGENEIC BMT
Li, J.-M.1, Darlak, K.A.1, Lu, Y.1, Harris, W.1, Jaye, D.L.2,
Waller, E.K.1 1Emory University, Atlanta, GA; 2Emory University,
Atlanta, GA
Based on a clinical association of donor plasmacytoid dendritic cell
(DC) content with leukemia relapses after allo BMT (Waller, Blood
2001), we previously reported that donor CD11b- DC enhanced
IFN-g synthesis and GvL activity of donor T-cells, while CD11b1
DC resulted in increased IL-10 production and decreasedGvL func-
tion by donor T-cells in allo BMT mouse models (Li, Blood 2007).
In this study, we tested mechanisms whereby donor DC in the graft
modulate donor T-cell activation in a MHC-mismatched (C57BL/
6/B10.BR) allo BMT. Recipients received 11 Gy irradiation fol-
lowed by tail vein injection of purified donor HSC, DC subsets
and T-cells two days later. Allografts consisted of 5 104 FACS-pu-
rified donor BM CD11b- DC or CD11b1 DC plus 3  103
c-kit1sca-11lineage- HSC in combination with either 3  105
T-cells or no additional T-cells. In vivo donor-derived T-cell prolif-
eration was assessed by CFSE staining. Serum and intracellular cyto-
kines (Th1: IL-12, IFN-g, IL-2, and TNF-a and Th2: IL-4, IL-5,
and IL-10) were tested by ELISA and flow cytometry. Costimulatory
molecule expression(CD40, CD80, ICOSL, PD-L1 and PD-L2)
was measured by flow cytometry following recovery of GFP1 donor
DC on day110 post-transplant. We found that donor CD8 T-cells
had higher levels of Ki-67 expression and proliferation than donor
CD4 T-cells 3 days post-transplant following transplantation with
CD11b- DC compared with CD11b1 DC, and without donor DC
(p\ 0.001). Both CD11b- DC and CD11b1 DC had similar level
of expression of CD40, CD80, and ICOSL in BM, in lymph nodes
and in spleen at 10 days post-transplant, but CD11b1 donor DC re-covered from BM had much higher levels of PD-L1 than CD11b-
DC,while CD11b-DC in all tissues had higher levels of PD-L2.Do-
nor CD11b- DC enhanced Th1 cytokine production of donor
T-cells, while donorCD11b1DCelevatedTh2 cytokine production
compared with T-cell alone. In conclusion: Donor CD11b- DC en-
hanced donor T-cell proliferation, especially CD8T-cells compared
with donor CD11b1 DC or recipients of T-cells alone. Homing of
donor DC to lymphoid organs and expression of costimulatory mol-
ecules on donor CD11b- and CD11b1DC subsets in vivo were sim-
ilar, suggesting that the differences observed in donor T-cell
activation and proliferation in distinct donor DC subset is likely
due to local production of cytokines by donor DC. The limited
GvHD seen with T-cells injected with CD11b- DC may be due to
differential expression of PD-L2 compared with CD11b1 DC.332
C-FLIP EXPRESSION DETERMINES LOW SENSITIVITY OF TYPE 17 T
HELPER CELLS TO ACTIVATION-INDUCED CELL DEATH
Yu, Y.1, Iclozan, C.2, Anasetti, C.3, Dong, C.4, Yu, X.-Z.5 1H. LeeMoffitt
Cancer Center and Research Institute, Tampa, FL; 2M.D. Anderson Can-
cer Center, Houston, TX
T cell apoptosis induced by repeated TCR stimulation, known as
activation-induced cell death (AICD), plays an important role in T
cell tolerance. Pro-inflammatory, IL-17-producing CD41 T cells
(Th17 cells) have been recently identified as a unique T helper sub-
set. Preliminary work from our lab indicated that Th17 cells partic-
ipate in the pathogenesis of acute graft-versus-host disease (GVHD).
In this study, we compared the susceptibility of polarized Th1 and
Th17 effectors to AICD in vitro and in vivo. We found that Th17 ef-
fectors were significantly less susceptible to AICD upon TCR re-
stimulation compared to Th1 effectors. It was further confirmed
by Th17 effectors generated from il17f/rfp knock-in mice, RFP1
(Th17) cells were indeed more resistant to AICD than RFP- (non-
Th17) cells. Resistance of Th17 cells to AICD was also observed
when Th17 cells were co-cultured with Th1 cells in vitro or co-in-
jected with Th1 cells in vivo in allogeneic recipients. To explore
the molecular mechanism of AICD resistance in Th17 cells, we
found that Th17 cells were defective in expression of FasL and in ac-
tivation of caspases, but highly expressed anti-apoptotic protein c-
FLIP as compared to Th1 cells. Given that Th17 cells were resistant
to AICD when co-cultured with Th1 cells that express high levels of
FasL, we hypothesized that Fas-signaling was impaired on Th17 ef-
fectors. After knocking down c-FLIP with its specific siRNA, Th17
cells upregulated FasL and underwent rapid apoptosis uponTCR re-
stimulation, indicating that Th17 cells are resistant to AICD likely
because the high level of c-FLIP prevents Fas-mediated apoptosis.
These results suggest the resistance of Th17 cells to AICD as addi-
tional mechanism that contributes to the high pathogenicity of Th17
cells in autoimmune diseases and GVHD. Our finding also
strengthens the rationale to use tumor-specific Th17 cells for adop-
tive cell therapy in cancer.333
MESENCHYMAL STEM CELL INFUSION AS PREVENTION FOR GRAFT RE-
JECTION AND GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMA-
TOPOIETIC CELL TRANSPLANTATION WITH NONMYELOABLATIVE
CONDITIONING FROM HLA-MISMATCHED DONORS: A PILOT STUDY
Baron, F., Willems, E., Lechanteur, C., Baudoux, E., Frere, P.,
Hafraoui, K., Fillet, G., Beguin, Y. University of Lie`ge, Belgium
Background: Allogeneic hematopoietic cell transplantation
(HCT) following nonmyeloablative conditioning has been an effec-
tive treatment for many pts with hematological malignancies who
have a HLA-matched related or unrelated donor. However, results
of nonmyeloablative HCT in pts with HLA-mismatched donors
have been disappointing due to high incidence of graft rejection
and severe acuteGVHD.Recent studies have suggested that infusion
of mesynchymal stem cells (MSC) the day of HCT might promote
engraftment and prevent acute GVHD after myeloablative alloge-
neic HCT. This prompted us to investigate whether MSC infusion
a few hours before HCT could allow non-myeloablative HCT
from HLA-mismatched donors to be performed safely (i.e. with
a 100-day incidence of nonrelapse mortality\35%).
120 Poster Session-IIMethods: 20 pts with hematological malignancies were given
MSC (1–2  10E6 cells/kg) from third party donors a few hours be-
fore PBSC from HLA-mismatched unrelated donors, after condi-
tioning with 2 Gy TBI and fludarabine 90 mg/m2. Postgrafting
immunosuppression included tacrolimus (day -3 to 1180; tapered
by day 1365) and mycophenolate mofetil (tid days 0 to 142).
HLA-compatibility was assessed at the HLA-A, -B, -C, -DRBI and
DQBI loci. 12 pairs weremismatched for at least oneHLA class I an-
tigen (including 4 pairs who were also mismatched for 1 HLA-class
II antigens (n 5 3) or 1 HLA-class I allele (n 5 1)), 1 pair was mis-
matched for 2 HLA class II alleles, and 7 pairs were mismatched
for a single HLA class I (n 5 4) or HLA class II (n 5 3) alleles.
Results: Median follow-up for surviving pts was 219 (range, 13–
519) days, and 17pts are already evaluable for day 100nonrelapsemor-
tality (primary endpoint).Thus far, 1 patientwith secondaryAMLhad
primary graft rejection, while the remaining pts had sustained engraft-
ment.Median donor T-cell chimerism levels on days 28, 100, 180 and
365 after HCT were 91%, 97%, 96%, and 98%, respectively. Grade
II, III and IV acute GVHD were seen in 4, 2 and 0 pts, respectively.
Two pts died of non-relapse causes on days 74 and 114 after HCT,
while 3 pts died of disease progression. Projected 1-yr overall and pro-
gression-free survivals were 74% and 62%, respectively.
Conclusions: HLA-mismatched nonmyeloablative HCT with
MSC co-infusion appeared to be safe. These encouraging results,
suggesting improved outcomes compared to similar pts not co-
infused withMSC, should be confirmed in a larger multicenter study.
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ANTITHYMOCYTE GLOBULINS (ATG) AS PART OF THE MYELOABLATIVE
CONDITIONING (MAC) REGIMEN CAN REDUCE THE RISK OF SEVERE
GRAFT-VS.-HOST DISEASE (GVHD) AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLO-SCT) FROM MATCHED-UNRELATED DONORS
(MUD) [A SFGM-TC STUDY]
Mohty, M.1, Balere, M.L.2, Socie, G.3, Milpied, N.4, Ifrah, N.5,
Kuentz, M.6, Harousseau, J.L.1, Vernant, J.P.7, Michallet, M.8,
Buzyn, A.9, Cahn, J.Y.10, Bourhis, J.H.11, Blaise, D.12, Raffoux, C.2,
Esperou, H.2, Yakoub-Agha, I.13 1CHU de Nantes, Nantes, France;
2Agence de Biomedecine, Paris, France; 3Hopital Saint-Louis, Paris,
France; 4CHU de Bordeaux, Bordeaux, France; 5CHU d’Angers, Angers,
France; 6Hopital HenriMondor, Creteil, France; 7Hopital La Pitie, Paris,
France; 8CHU de Lyon, Lyon, France; 9Hopital Necker, Paris, France;
10CHU de Grenoble, Grenoble, France; 11 Institut Gustave Roussy, Paris,
France; 12 Institut Paoli-Calmettes, Marseille, France; 13CHU de Lille,
Lille, France
Here, we report the results of a multicenter retrospective study an-
alyzing the effect of ATG, incorporated within theMAC regimen for
MUD-transplants in leukemic patients.The purpose of the studywas
to compare the incidence and severity of acute and chronicGVHDas
well as overall outcome. 171 adult patients with acute leukemia and
MDS, for whom detailed allelic HLA typing (4 digits) was available,
were included. 81% of patients were transplanted from 10/10 allelic
MUD, and 19% from aMUDwith at least one allelic difference. 120
patients (70%) did not receive ATG (‘‘no-ATG’’ group), while 51 pa-
tients received ATG (‘‘ATG’’ group; Thymoglobuline*, Genzyme in
all cases) as part of theMACregimen.Except for a significantly higher
number of allelic differences between recipient and donor (33% vs.
13%; P 5 0.002), the ‘‘no-ATG’’ and ‘‘ATG’’ groups were strictly
comparable. With a median follow-up of 30.3 (range, 2.6–68.1)
months, grade 0–1 and 2–4 acute GVHD occurred in 74 (46%) and
88 patients (54%) respectively, with grade 3–4 acute GVHD being
significantly lower in the ‘‘ATG’’ group (18% vs. 32%; P 5 0.04).
Limited and extensive chronic GVHD were observed in 22 and
25% of assessable patients respectively, with extensive chronic
GVHD being significantly lower in the ‘‘ATG’’ group (5% vs.
33%; P 5 0.001). Interestingly, patients from the ‘‘ATG’’ group
had a higher incidence of limited chronic GVHD (33% vs. 18%;
P5 0.06).Moreover, infection-relatedmortality was comparable be-
tween both groups (23% vs. 27%, P5NS). Also, NRMwas compa-
rable between both groups (30% vs. 29%; P 5NS). In multivariate
analysis, an HLA allelic mismatch and the non-use of ATG were as-
sociatedwith an increased risk of grade 3–4 acuteGVHD(RR52.80,
95%CI, 1.5–5.3, P5 0.001; andRR5 2.4, 95%CI, 1.1–5.0, P5 0.02
respectively). Similarly,multivariate analysis showed that the absence
of use of ATGwas the unique parameter associated with an increasedrisk of extensive chronic GVHD (RR 5 6.9; 95%CI, 1.7–29.0, P 5
0.008). Finally, LFS andOS at 2 years were not significantly different
between the ‘‘no-ATG’’ and ‘‘ATG’’ group (48.8% vs. 41.3%, P 5
NS; and 53.6% vs. 54.3%, P5NS; respectively). These results sug-
gest a global long-term beneficial effect of ATGwhen used as part of
the MAC regimen prior to allo-SCT from MUD (especially in the
HLAmismatch setting). Suchprotective effect of ATGagainst severe
GVHD can be likely achieved without an increased risk of infections
or leukemia recurrence.335
HUMAN MEMORY T CELL S ELICIT DECREASED CYTOTOXICITY AGAINST
ALLOGENEIC TARGETS
Zheng, Q., Deoliveira, D., Chao, N.J., Chen, B.J. Duke University Med-
ical Center, Durham, NC
Several groups have independently demonstrated that memory T
cells do not induce graft-versus-host disease in several different ani-
mal models. To test whether the same concept applies to humans, we
compared the ability of memory T cells to respond to alloantigens
with that of naive T cells. Purified T cells were first obtained from
peripheral blood from healthy donors and then separated into mem-
ory and naive T cell subsets based on the expression of CD45RA
(memory: CD45RA-, naive: CD45RA1). Memory T cells were
then tested for their ability to respond to alloantigens by using sev-
eral standard in vitro assays. In contrast to the mouse data, memory
T cells proliferated equally well as naiveT cells did inmixed lympho-
cyte culture. Despite the similar proliferative responses against allo-
antigens as those mediated by naive T cells, these same memory T
cells failed to kill the allogeneic targets. Limiting dilution assay dem-
onstrated that the frequency of allospecific cytotoxicity T cells was
6–68.5 fold less in memory T cells than that in naive T cells. Inter-
leukin 2 was unable to restore the cytotoxicity against alloantigens.
The results from skin explant assay further suggested that, in con-
trast to naive T cells, memory T cells might not be able to induce
graft-versus-host disease. These data suggest that human memory
T cells contain less alloantigen-specific cytotoxicity T cells and
may not cause graft-versus-host disease upon in vivo transfer. Since
clinical grade antibody is now available, this approach will soon be
tested in humans for the prevention of graft-versus-host disease.336
PROGNOSTIC FACTORS AND OUTCOMES OF SEVERE GASTROINTESTINAL
GRAFT-VS-HOST DISEASE (GI GVHD) AFTER ALLOGENEIC HEMATOPOI-
ETIC CELL TRANSPLANTATION
Castilla-LLorente, C.1,2, Nash, R.A.1, McDonald, G.B.1, Storer, B.E.1,
Martin, P.J.1 1Fred Hutchinson Cancer Research Center, University of
Washington, Seattle, WA; 2Hospital Morales Meseguer, Murcia, Spain
Treatment of severe GI GVHD poses a challenge, as little prog-
ress has been made in developing better treatments, survival remains
poor and it is difficult to know the ultimate severity of GVHD and
the outcome at the onset of symptoms. We reviewed the records of
117 consecutive patients transplanted between 2000–2005 who de-
veloped stages 3–4 GI GVHD. Data were collected for more than
20 parameters including stool volume, abdominal pain, melena, up-
perGI symptoms, serum albumin, number of treatments, visual find-
ings at endoscopy and histopathologic grade of GI biopsies. Clinical
parameters were measured as the peak value during each 14 day pe-
riod starting from 2 weeks before the diagnosis of GI GVHD to the
resolution of symptoms, loss of follow-up or patient death. Median
onset of symptoms was day 29 (range 4 – 135); 11 (9.6%) patients
presented after day 80. Mean daily stool volume at diagnosis was
1831.12 61438.16mL/day. At onset of GI symptoms, 56% of pa-
tients had $ stage 1 skin GVHD and 62% had $ stage 1 liver
GVHD. At onset, 78% had upper GI symptoms and 55% of patients
presented with severe abdominal pain. Within the first 2 weeks after
the diagnosis of GI GVHD, 62 (53%), 37 (31.6%), 4 (3.4%), 13
(11.2%) and 1 (0.8%) patients had a peak GI stage of 4, 3, 2, 1 and
0 respectively. All patients received high dose prednisone/predniso-
lone as initial treatment; 67 received 2nd line therapy; and 32 received
three or more lines of treatment. Non-relapse mortality was 71%
and 41% at 1 year after transplant in patients with steroid-refractory
and steroid-responsive GVHD, respectively. Overall survival was
